Anti-Glycoprotein Antibody Development Service

Equipped with world-leading technology platforms and professional scientific staff, Creative Biolabs has developed an advanced Anti-Gly™ platform for custom anti-glycoprotein antibody development. Several cutting-edge antibody discovery technologies, including phage display technology, hybridoma technology, and antigen-specific B lymphocytes sorting technology, are employed on our Anti-Gly™ platform. With years of experience in the discovery of anti-glycoprotein monoclonal antibodies (mAbs), we can offer high-quality customized services by adjusting protocols to meet even the most specific requirements.

Technologies for Anti-Glycoprotein mAbs Discovery in Creative Biolabs

Phage Display Technology for Anti-Glycoprotein mAbs Discovery

Phage display technology is a powerful tool to discovery mAbs for therapeutic or diagnostic purposes. Creative Biolabs has long-term devoted to the development and application of phage display technology. Our scientists can offer high-quality phage display scFv/Fab/V_HH library construction and custom phage display library screening services for the discovery of anti-glycoprotein mAbs. Based on our advanced phage display platform, we have tailored hundreds of scFv/Fab libraries construction and screening services according to our clients’ demands precisely.

Hybridoma Technology for Anti-Glycoprotein mAbs Discovery

Hybridoma technology has greatly increased the specificity of antibodies as well as permitted large-scale production of specific antibodies. To discover anti-glycoprotein mAbs, Creative Biolabs provides a full range of services based on our state-of-the-art hybridoma platform, including gene synthesis, antigen expression to antibody purification and labeling. The quantity of antibodies can be small-scaled for research applications or massive preparation for diagnostic industry. We can offer high-quality mAbs for research, diagnostic, as well as therapeutic antibody developments.

Antigen-Specific B Lymphocytes Sorting Technology for Anti-Glycoprotein mAbs Discovery

Creative Biolabs has developed antigen-specific B cells sorting platform to retrieve native antibodies with extremely high in vivo specificity and affinity. We employ fluorescent activated cell sorting (FACS), laser-capture microdissection (LCM), microengraving and droplet microfluidics technology to isolate single antigen-specific B cells. Combined with next-generation sequencing (NGS), this cutting-edge platform can be used to isolate mAbs with paired heavy chain and light chain from diverse species, such as humans, rabbits, rats, mice, chickens, camelids, sheep, monkeys, dogs, cows, etc.

Key Features and Advantages of Anti-Gly™ Platform

A full range of glycoprotein production systems, including Escherichia coli, mammalian cells, yeast cells, insect cells, and plant cells.
Various screening strategies for anti-glycoprotein antibody discovery
Diverse species available
High sensitivity and high-throughput
Cost-effective and short turnaround
Ph.D. level scientists with extensive experiences

Scientists from Creative Biolabs employ proprietary protocols and various strategies to identify anti-glycoprotein mAbs with higher affinity and desired specificity. We can tailor different strategies for the discovery of anti-glycoprotein antibody to meet our clients’ project development goal in a time-saving manner. Through our high-throughput anti-glycoprotein mAbs discovery system, clients could accelerate their research by reducing project costs and timelines. Please feel free to contact us for more information and a detailed quote.

Published data

Human cytomegalovirus (HCMV) belongs to the β-herpesvirus family. As a widespread pathogen, HCMV is common and pathogenic in humans. Although most infected people have no obvious symptoms, individuals with compromised immune systems may be at risk for serious complications. Studies have shown that potent neutralizing monoclonal antibodies (mAbs) are one of the promising drugs for the treatment of HCMV infection. Due to the cell tropism of HCMV, an antibody treatment targeting the viral glycoprotein cannot protect all cells from viral infection. Therefore, in this study, the authors combined two neutralizing mAbs, that was, fused 2-18 scFv with the heavy chain C-terminus of mAb 3-25, to develop a new type of IgG scFv bispecific antibody. This antibody combined the therapeutic advantages of two antiviral antibodies, which had a high affinity for the targeted glycoprotein B and showed broad and effective neutralizing activity after 21 days. In addition, the bispecific antibody developed could effectively neutralize virus infection in multiple cell lines and inhibit virus transmission. This research result shows that the development of fully functional IgG-scFv bispecific neutralizing antibodies is a new strategy for the treatment of HCMV infection.

Fig.1 Construction and characterization of bispecific antibodies.¹

FAQs

Q1: How to ensure high specificity and high affinity of antibodies during development?

A1: During the development process, we use a variety of methods to ensure high specificity and high affinity of antibodies. First, we carefully design specific antigen epitopes in the antigen design stage. Secondly, we use high-quality phage display and B cell sorting technology to improve antibody affinity through multiple rounds of screening in the screening process. Finally, we verify the specificity and affinity of the antibody, thereby ensuring that the final antibody meets high standards.

Q2: Which species can you provide antibody development services for?

A2: Our diversified platform processes samples from different species (such as rabbits, mice, dogs, cows, etc.), provides corresponding antibody development services, and provides in vitro and in vivo evaluation services for the developed antibodies to verify the efficacy and safety of antibodies.

Q3: Could you provide a complete antibody research report and data analysis?

A3: Yes, we will provide detailed research reports and data analysis for each project. The report includes antigen design, immunization, screening process, affinity test results, functional verification results, and many other contents. We will also provide antibody sequence analysis data and suggestions to help clients better understand and use our antibody products.

Customer Review

Efficient Phage Display Technology
"We are very satisfied with the anti-glycoprotein antibody development service provided by Creative Biolabs. The phage display technology they use is extremely efficient and has successfully developed a series of high-affinity and high-specificity anti-glycoprotein antibodies for us. The entire development process is extremely efficient and far exceeds our expectations."

Customized And Flexible Antibody Development Program
"We are impressed by Creative Biolabs' ability to flexibly customize their program to meet our specific requirements for anti-glycoprotein mAbs. They use an antigen-specific B cell sorting platform, and the mAbs isolated have excellent in vivo specificity and affinity, which highlights their technical strength."

Reference

Su, Hang, et al. "Potent bispecific neutralizing antibody targeting glycoprotein B and the gH/gL/pUL128/130/131 complex of human cytomegalovirus." Antimicrobial agents and chemotherapy 65.3 (2021): 10-1128. Distributed under Open Access license CC BY 4.0, without modification.

For Research Use Only.